Point72 Asia (Singapore) Pte. Ltd. Editas Medicine, Inc. Transaction History
Point72 Asia (Singapore) Pte. Ltd.
- $532 Billion
- Q3 2024
A detailed history of Point72 Asia (Singapore) Pte. Ltd. transactions in Editas Medicine, Inc. stock. As of the latest transaction made, Point72 Asia (Singapore) Pte. Ltd. holds 93,789 shares of EDIT stock, worth $112,546. This represents 0.06% of its overall portfolio holdings.
Number of Shares
93,789Holding current value
$112,546% of portfolio
0.06%Shares
2 transactions
Others Institutions Holding EDIT
# of Institutions
248Shares Held
57MCall Options Held
410KPut Options Held
394K-
Black Rock Inc. New York, NY7.78MShares$9.34 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.68MShares$8.02 Million0.0% of portfolio
-
Deep Track Capital, LP Greenwich, CT4.9MShares$5.88 Million0.62% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny3.35MShares$4.02 Million0.01% of portfolio
-
State Street Corp Boston, MA2.46MShares$2.95 Million0.0% of portfolio
About Editas Medicine, Inc.
- Ticker EDIT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 68,737,200
- Market Cap $82.5M
- Description
- Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads t...